Adaptive Biotechnologies
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Adaptive Biotechnologies generated cash of -$156,324,000, which is more than the previous year. Cash used in financing activities reached the amount of $2,245,000 last year. Net change in cash is therefore -$24,432,000.
Cash Flow
| 2017 | -34.85M | 36.43M | 50.03M |
|---|---|---|---|
| 2018 | -32.25M | 736K | 1.24M |
| 2019 | 205.40M | -481.69M | 319.91M |
| 2020 | -149.68M | -117.04M | 293.58M |
| 2021 | -192.72M | 181.21M | 27.14M |
| 2022 | -183.94M | 2.90M | 132.26M |
| 2023 | -156.32M | 129.64M | 2.24M |
ADPT Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 92.42M | 141.20M | 125.57M | 98.71M | 55.09M | 85.36M | 33.75M |
Operating activities | |||||||
Net income | -225.25M | -200.36M | -207.29M | -146.22M | -68.60M | -46.44M | -42.83M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 22.23M | 20.92M | 13.95M | 8.47M | 7.79M | 6M | 5.79M |
Stock-based compensation expense | 62.90M | 55.47M | 43.25M | 24.76M | 13.12M | 0 | 7.00M |
| Deferred income tax benefit | 62.90M | 55.47M | 43.25M | 24.76M | 13.12M | 0 | 7.00M |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | 2.03M | -22.64M | -7.36M | 2.61M | -7.81M | 775K | -2.42M |
Inventories | 1.38M | 817K | -5.2M | -4.99M | -1.23M | -3.04M | -2.69M |
Accounts payable | -5.40M | 7.11M | 5.22M | 5.24M | -2.42M | 1.86M | -1.84M |
Cash generated by operating activities | -156.32M | -183.94M | -192.72M | -149.68M | 205.40M | -32.25M | -34.85M |
Investing activities | |||||||
Purchases Of Investments | -429.55M | -278.77M | -316.54M | -694.96M | -884.21M | -146.50M | -125.18M |
Investments In Property Plant And Equipment | -10.69M | -16.34M | -61.74M | -18.80M | -11.2M | -6.31M | -2.50M |
Acquisitions Net | 0 | -19.25M | -181.21M | 98.24M | 470.49M | 0 | 85K |
Cash generated by investing activities | 129.64M | 2.90M | 181.21M | -117.04M | -481.69M | 736K | 36.43M |
Financing activities | |||||||
Common Stock Issued | 2.24M | 7.89M | 26.71M | 272.16M | 320.85M | 0 | 50.04M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | 0 | 124.37M | 0 | 0 | 0 | 0 | 0 |
Cash used in financing activities | 2.24M | 132.26M | 27.14M | 293.58M | 319.91M | 1.24M | 50.03M |
Net Change In Cash | -24.43M | -48.77M | 15.62M | 26.86M | 43.62M | -30.27M | 51.60M |
Cash at end of period | 67.99M | 92.42M | 141.20M | 125.57M | 98.71M | 55.09M | 85.36M |
| Data source | Data source | Data source | Data source | Data source |